Clinical analysis of autologous peripheral blood stem cell transplantation in patients with malignant Lymphoma

Objectives: To investigate the effect and safety of high dose chemotherapy (HDC) with autologous peripheral blood stem cell transplantation (APBSCT) in treating malignant lymphoma. Methods: 18 malignant lymphoma patients were treated with high dose chemoradiotherapy with APBSCT, there were 15 cases with non-hodgkin's lymphoma and 3 with Hodgkin's lymphoma. Primary treatment:1 NHL was CTX 3. 6 g/m2+total body irradiation. Others were CTX 3. 6 g/m2, Ara-C 1. 5 g/m2, VP-16 800 mg/ m2, BCNU 450 mg/m2, and complementary irradiation in the primary sites after transplantation. Results: After mobilization, the numbers of mono-nucler cell (MNC) and CD34+ were 4. 59×108/kg(range, 3. 42×108/kg-7. 46×108/kg), 5. 15×106/kg(range, 1. 74×106/kg-10. 81×106/kg) respectively in this study. Among these patients, 17 cases achieved complete response(CR) and 1 case achieved partial response (PR). The median follow up time was 10 (range, 1-56) months. All of patients were alive at that time. Conclusions: HDC combined with APBSCT is a safe and effective method in the treatment of malignant lymphoma and worth to further clinical study.